Stefan Willmann

Berlin, BE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 56 publications

Physiologically-Based Pharmacokinetic Modeling to Support Pediatric Clinical Development: An IQ Working Group Perspective on the Current Status and Challenges.

Physiologically-Based Pharmacokinetic Modeling to Support Pediatric Clinical Development: An IQ Working Group Perspective on the Current Status and Challenges.

Journal: CPT: pharmacometrics & systems pharmacology

Published: May 30, 2025

Population pharmacokinetic-pharmacodynamic model of elinzanetant based on integrated clinical phase I and II data.

Population pharmacokinetic-pharmacodynamic model of elinzanetant based on integrated clinical phase I and II data.

Journal: CPT: pharmacometrics & systems pharmacology

Published: April 14, 2024

A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis.

A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis.

Journal: Kidney international

Published: October 20, 2023

The Importance of Assessing Drug Pharmacokinetics and Pharmacodynamics in the Obese Population During Drug Development.

The Importance of Assessing Drug Pharmacokinetics and Pharmacodynamics in the Obese Population During Drug Development.

Journal: Journal of clinical pharmacology

Published: July 14, 2023

Longitudinal observations of TFPI levels in paediatric Haemophilia A patients.

Longitudinal observations of TFPI levels in paediatric Haemophilia A patients.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: April 04, 2023

Anticoagulation in pediatric cancer-associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr.

Anticoagulation in pediatric cancer-associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr.

Journal: Blood advances

Published: June 29, 2022

Nifurtimox for Treatment of Chagas Disease in Pediatric Patients: the Challenges of Applying Pharmacokinetic-Pharmacodynamic Principles to Dose Finding.

Nifurtimox for Treatment of Chagas Disease in Pediatric Patients: the Challenges of Applying Pharmacokinetic-Pharmacodynamic Principles to Dose Finding.

Journal: The AAPS journal

Published: April 19, 2022

Population pharmacokinetics of riociguat in a pediatric population (aged ≥ 6 years) with pulmonary arterial hypertension.

Population pharmacokinetics of riociguat in a pediatric population (aged ≥ 6 years) with pulmonary arterial hypertension.

Journal: Pediatric pulmonology

Published: April 04, 2022

Model-informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease.

Model-informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease.

Journal: CPT: pharmacometrics & systems pharmacology

Published: March 31, 2022

Riociguat in children with pulmonary arterial hypertension: The PATENT-CHILD study.

Riociguat in children with pulmonary arterial hypertension: The PATENT-CHILD study.

Journal: Pulmonary circulation

Published: December 16, 2021

Population Pharmacokinetics of Nifurtimox in Adult and Pediatric Patients With Chagas Disease.

Population Pharmacokinetics of Nifurtimox in Adult and Pediatric Patients With Chagas Disease.

Journal: Journal of clinical pharmacology

Published: December 16, 2021

Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study.

Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study.

Journal: Journal of clinical pharmacology

Published: June 29, 2021

Showing 1-12 of 56

Last Updated: 09/26/2026